Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2766145 | 0.81 | RAB9A (0.71) | L3MBTL1NPC1RAB9ASMN1; SMN2ALK | |
| SCHEMBL427627 | 0.81 | L3MBTL1 (1.00) | L3MBTL1NPC1RAB9ASMN1; SMN2ALK | |
| SCHEMBL3464137 | 0.79 | L3MBTL1 (0.56) | L3MBTL1NPC1RAB9ASMN1; SMN2ALK | |
| SCHEMBL1160360 | 0.78 | NPC1 (0.67) | L3MBTL1NPC1RAB9ASMN1; SMN2ALK | |
| SCHEMBL14097585 | 0.78 | L3MBTL1 (0.92) | L3MBTL1NPC1RAB9ASMN1; SMN2ALK | |
| SCHEMBL792992 | 0.78 | NPC1 (1.00) | L3MBTL1NPC1RAB9ASMN1; SMN2ALK | |
| SCHEMBL2360295 | 0.78 | NPC1 (0.67) | L3MBTL1NPC1RAB9ASMN1; SMN2ALK | |
| SCHEMBL17183457 | 0.78 | L3MBTL1 (0.66) | L3MBTL1NPC1RAB9ASMN1; SMN2ALK | |
| SCHEMBL15908507 | 0.78 | NPC1 (0.67) | L3MBTL1NPC1RAB9ASMN1; SMN2ALK | |
| SCHEMBL3051778 | 0.77 | NPC1 (0.61) | L3MBTL1NPC1RAB9ASMN1; SMN2ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| WO-2023004280-A1 | SELECTIVE PYRAZOLE LRRK2 INHIBITORS AND METHODS FOR USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023004280-A1 | SELECTIVE PYRAZOLE LRRK2 INHIBITORS AND METHODS FOR USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-01-26 | — | — | WO | disclosed |
| US-20200255434-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, INC. | 2020-08-13 | — | — | US | disclosed |
| WO-2020114212-A1 | 4-(3-HETEROCYCLYL-1-BENZOYL) PYRAZOLE COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR, HERBICIDE COMPOSITION THEREOF AND USE THEREOF | 青岛清原化合物有限公司 | 2020-06-11 | — | — | WO | disclosed |
| WO-2012000519-A1 | ARYL- AND HETEROARYLAMID DERIVATIVES AS PDE10A ENZYME INHIBITOR | H. LUNDBECK A/S (DK) | 2012-01-05 | — | — | WO | disclosed |
| US-7589199-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-20060106218-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2006-05-18 | — | — | US | disclosed |
| WO-1993001184-A1 | IMIDAZOLES INHIBITORS AS ACAT AND THROMBOXANE TXA2 | RHONE-POULENC RORER LIMITED (GB) | 1993-01-21 | — | — | WO | disclosed |
| EP-0522887-A1 | Imidazoles as ACAT- and thromboxane TxA2 inhibitors | RHONE-POULENC RORER LIMITED (GB) | 1993-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255434-A1 | INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | L3MBTL1 757/4885NPC1 4016/4885RAB9A 2357/4885 |
| US-12043613-B2 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | L3MBTL1 186/4885NPC1 232/4885RAB9A 752/4885 |
| US-20060106218-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | L3MBTL1 1589/4885NPC1 635/4885RAB9A 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.